What is Annovis Bio's operating income?

Annovis Bio's total operating income in 2025 was -$29.70 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $29.70 million

Annovis Bio (ANVS) Financials

$1.74 -0.06 (-3.06%)

Closing price 07/16/2026 03:59 PM Eastern

Extended Trading

$1.72 -0.02 (-1.15%)

As of 07/16/2026 07:35 PM Eastern

Compare

Annual Income Statements for Annovis Bio

This table shows Annovis Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-0.99	-5.46	-14	-25	-56	-25	-29
Consolidated Net Income / (Loss)	-0.99	-5.46	-14	-25	-56	-25	-29
Net Income / (Loss) Continuing Operations	-0.99	-5.46	-14	-25	-56	-25	-29
Total Pre-Tax Income	-0.99	-5.46	-14	-25	-56	-25	-29
Total Operating Income	-1.61	-6.64	-15	-26	-45	-27	-30
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	1.61	6.64	15	26	45	27	30
Selling, General & Admin Expense	0.83	3.59	6.06	9.00	6.24	6.70	4.48
Research & Development Expense	0.78	3.05	8.48	17	39	20	25
Total Other Income / (Expense), net	0.61	1.18	0.05	0.18	-11	2.10	0.84
Interest & Investment Income	-0.04	0.05	0.01	0.18	0.67	0.33	0.70
Other Income / (Expense), net	0.66	1.13	0.04	0.00	-12	1.77	0.14
Basic Earnings per Share	($3.51)	($0.87)	($1.90)	($3.10)	($6.23)	($2.02)	($1.40)
Weighted Average Basic Shares Outstanding	282.61K	6.31M	7.63M	8.16M	9.02M	12.18M	20.55M
Diluted Earnings per Share	($3.51)	($0.87)	($1.90)	($3.10)	($6.23)	($2.31)	($1.40)
Weighted Average Diluted Shares Outstanding	282.61K	6.31M	7.63M	8.16M	9.02M	12.24M	20.55M
Weighted Average Basic & Diluted Shares Outstanding	282.61K	6.31M	8.16M	8.22M	11.01M	19.49M	28.36M

This table shows Annovis Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-15	-22	-1.07	-5.02	-13	-5.86	-5.54	-6.22	-7.26	-9.83	-18
Consolidated Net Income / (Loss)	-15	-22	-1.07	-5.02	-13	-5.86	-5.54	-6.22	-7.26	-9.83	-18
Net Income / (Loss) Continuing Operations	-15	-22	-1.07	-5.02	-13	-5.86	-5.54	-6.22	-7.26	-9.83	-18
Total Pre-Tax Income	-15	-22	-1.07	-5.02	-13	-5.86	-5.54	-6.22	-7.26	-9.83	-18
Total Operating Income	-15	-10	-7.81	-7.76	-4.39	-6.73	-6.28	-6.27	-7.43	-9.71	-18
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	15	10	7.81	7.76	4.39	6.73	6.28	6.27	7.43	9.71	18
Selling, General & Admin Expense	1.03	1.54	1.29	1.98	1.70	1.73	1.27	1.11	1.14	0.96	1.29
Research & Development Expense	14	8.90	6.51	5.79	2.69	5.01	5.01	5.16	6.29	8.75	17
Total Other Income / (Expense), net	0.15	-12	6.74	2.74	-8.25	0.87	0.75	0.05	0.17	-0.13	0.41
Interest & Investment Income	0.15	0.07	0.04	0.03	0.14	0.13	0.19	0.19	0.15	0.17	0.14
Other Income / (Expense), net	0.00	-	6.70	2.72	-8.39	0.74	0.56	-0.14	0.02	-0.30	0.27
Basic Earnings per Share	($1.63)	($2.34)	($0.10)	($0.44)	($0.97)	($0.51)	($0.32)	($0.32)	($0.37)	($0.39)	($0.63)
Weighted Average Basic Shares Outstanding	9.01M	9.02M	10.63M	11.31M	12.98M	12.18M	17.43M	19.49M	19.69M	20.55M	27.85M
Diluted Earnings per Share	($1.63)	($2.34)	($0.72)	($0.44)	($0.97)	($0.18)	($0.32)	($0.32)	($0.37)	($0.39)	($0.63)
Weighted Average Diluted Shares Outstanding	9.01M	9.02M	10.82M	11.31M	12.98M	12.24M	17.43M	19.49M	19.69M	20.55M	27.85M
Weighted Average Basic & Diluted Shares Outstanding	10.26M	11.01M	11.17M	13.05M	13.80M	19.49M	19.49M	19.49M	26.50M	28.36M	34.65M

This table details how cash moves in and out of Annovis Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.03	8.07	38	-17	-23	4.80	8.98
Net Cash From Operating Activities	-0.48	-3.97	-9.13	-17	-40	-22	-26
Net Cash From Continuing Operating Activities	-0.48	-3.97	-9.13	-17	-40	-22	-26
Net Income / (Loss) Continuing Operations	-0.99	-5.46	-14	-25	-56	-25	-29
Consolidated Net Income / (Loss)	-0.99	-5.46	-14	-25	-56	-25	-29
Non-Cash Adjustments To Reconcile Net Income	-0.73	2.60	4.70	9.15	16	2.01	1.66
Changes in Operating Assets and Liabilities, net	1.24	-1.11	0.66	-1.14	-0.23	0.68	1.58
Net Cash From Investing Activities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Cash From Financing Activities	0.44	12	47	0.00	17	27	35
Net Cash From Continuing Financing Activities	0.44	12	47	0.00	17	27	35
Issuance of Debt	0.53	-	-	-	-	-	35
Other Financing Activities, net	-0.09	0.01	47	0.00	0.01	8.03	0.00

This table details how cash moves in and out of Annovis Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-9.37	-0.60	-2.62	0.86	8.64	-2.08	12	-5.11	-1.84	4.25	-5.31
Net Cash From Operating Activities	-9.37	-9.36	-7.03	-3.38	-3.20	-8.29	-8.10	-5.11	-3.49	-8.93	-9.01
Net Cash From Continuing Operating Activities	-9.37	-9.36	-7.03	-3.38	-3.20	-8.29	-8.10	-5.11	-3.49	-8.93	-9.01
Net Income / (Loss) Continuing Operations	-15	-22	-1.07	-5.02	-13	-5.86	-5.54	-6.22	-7.26	-9.83	-18
Consolidated Net Income / (Loss)	-15	-22	-1.07	-5.02	-13	-5.86	-5.54	-6.22	-7.26	-9.83	-18
Non-Cash Adjustments To Reconcile Net Income	0.63	13	-6.33	-1.17	8.78	0.74	-0.06	0.64	0.42	0.65	-0.09
Changes in Operating Assets and Liabilities, net	4.71	0.13	0.37	2.81	0.66	-3.16	-2.50	0.48	3.35	0.25	8.68
Net Cash From Investing Activities	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Net Cash From Continuing Investing Activities	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Net Cash From Financing Activities	-	8.76	4.42	4.24	12	6.20	20	-	1.64	13	3.70
Net Cash From Continuing Financing Activities	-	8.76	4.42	4.24	12	6.20	20	-	1.64	13	3.70
Issuance of Common Equity	-	8.76	4.42	4.24	12	-1.82	20	-	1.64	-	3.70

This table presents Annovis Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1.12	8.12	46	36	10	14	21
Total Current Assets	0.75	8.12	46	36	5.75	14	20
Cash & Equivalents	0.00	8.07	46	28	5.75	11	20
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	0.37	0.00	0.00	0.00	4.45	0.00	1.55
Other Noncurrent Operating Assets	0.37	-	-	-	4.45	-	1.55
Total Liabilities & Shareholders' Equity	1.12	8.12	46	36	10	14	21
Total Liabilities	2.62	0.58	1.51	7.70	18	4.62	4.23
Total Current Liabilities	2.01	0.58	1.51	7.70	4.28	3.88	3.64
Accounts Payable	1.23	0.34	0.69	3.96	1.29	2.31	2.59
Accrued Expenses	0.78	0.24	0.82	3.74	2.99	1.58	1.04
Total Noncurrent Liabilities	0.61	0.00	0.00	0.00	14	0.74	0.60
Other Noncurrent Operating Liabilities	0.11	-	-	0.00	14	0.74	0.60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-8.58	7.54	44	28	-7.75	9.31	17
Total Preferred & Common Equity	-8.58	7.54	44	28	-7.75	9.31	17
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-8.58	7.54	44	28	-7.75	9.31	17
Common Stock	0.20	22	73	82	103	144	181
Retained Earnings	-8.78	-14	-29	-54	-110	-135	-164

This table presents Annovis Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	10	7.81	5.05	14	27	21	17	16
Total Current Assets	10	7.81	5.05	14	27	21	17	16
Cash & Equivalents	6.35	3.14	4.00	13	22	17	15	14
Prepaid Expenses	3.87	4.68	1.05	1.72	4.50	4.32	1.90	2.02
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities & Shareholders' Equity	10	7.81	5.05	14	27	21	17	16
Total Liabilities	3.56	11	6.80	7.30	2.68	3.12	4.03	13
Total Current Liabilities	3.56	4.87	4.06	5.39	2.50	2.81	3.73	13
Accounts Payable	1.93	4.11	3.39	4.10	1.37	0.97	2.11	5.28
Accrued Expenses	1.64	0.76	0.66	1.29	1.13	1.83	1.62	7.51
Total Noncurrent Liabilities	0.00	6.30	2.74	1.91	0.18	0.32	0.30	0.33
Other Noncurrent Operating Liabilities	-	6.30	2.74	1.91	0.18	0.32	0.30	0.33
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6.66	-3.35	-1.75	7.06	24	18	13	3.13
Total Preferred & Common Equity	6.66	-3.35	-1.75	7.06	24	18	13	3.13
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	6.66	-3.35	-1.75	7.06	24	18	13	3.13
Common Stock	95	108	115	136	164	165	167	184
Retained Earnings	-88	-111	-116	-129	-140	-147	-154	-181

This table displays calculated financial ratios and metrics derived from Annovis Bio's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	6,891,608.00	8,100,570.00	8,163,923.00	10,262,273.00	13,797,242.00	26,502,889.00
DEI Adjusted Shares Outstanding	0.00	6,891,608.00	8,100,570.00	8,163,923.00	10,262,273.00	13,797,242.00	26,502,889.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-0.79	-1.79	-3.10	-5.48	-1.78	-1.09
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-482.86%	-163.23%	-75.93%	-122.93%	56.18%	-18.58%
EBIT Growth	0.00%	-479.89%	-163.20%	-75.93%	-122.93%	56.18%	-18.58%
NOPAT Growth	0.00%	-313.56%	-118.93%	-75.49%	-76.53%	40.72%	-11.24%
Net Income Growth	0.00%	-451.18%	-165.23%	-74.83%	-121.90%	56.25%	-17.34%
EPS Growth	0.00%	75.21%	-118.39%	-63.16%	-100.97%	62.92%	39.39%
Operating Cash Flow Growth	0.00%	-733.26%	-129.98%	-89.58%	-130.85%	45.22%	-17.01%
Free Cash Flow Firm Growth	0.00%	0.00%	-86.06%	-99.55%	4.85%	-71.24%	37.48%
Invested Capital Growth	0.00%	46.71%	-123.17%	95.45%	-24,835.04%	90.79%	-115.47%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	-38.02%	-40.98%	-7.96%	-34.15%	18.03%	-15.70%
EBIT Q/Q Growth	0.00%	-37.96%	-40.98%	-7.96%	-34.15%	18.03%	-15.70%
NOPAT Q/Q Growth	0.00%	-18.54%	-38.10%	-7.96%	-6.23%	12.19%	-11.12%
Net Income Q/Q Growth	0.00%	-37.98%	-40.97%	-7.70%	-34.73%	39.93%	-15.95%
EPS Q/Q Growth	0.00%	33.08%	-32.87%	-6.53%	-28.99%	48.32%	-17.65%
Operating Cash Flow Q/Q Growth	0.00%	-21.90%	-12.34%	-11.89%	-16.82%	4.70%	-2.57%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-54.45%	5.37%	33.98%	-100.89%	12.64%
Invested Capital Q/Q Growth	0.00%	-290.38%	-28.70%	-102.08%	-4,553.34%	77.67%	-25.86%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	104.31%	99.14%	99.91%	99.28%	98.83%	98.67%	97.63%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	11.55%	1,055.01%	-55.68%	-69.57%	-546.40%	-3,159.09%	-220.61%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	11.55%	1,055.01%	-55.68%	-69.57%	-546.40%	-3,159.09%	-220.61%
Return on Equity Simple (ROE_SIMPLE)	11.55%	-72.43%	-32.56%	-89.43%	725.14%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.12	-4.65	-10	-18	-32	-19	-21
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.76%	-325.72%	-16.04%	-20.17%	-144.61%	-72.41%	-53.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	406.72%	-200.76%	-123.35%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-0.95	-5.51	-15	-26	-57	-25	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.95	-5.51	-15	-26	-57	-25	-30
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	6.89	3.20	3.87	0.00	7.46	5.44
Price to Tangible Book Value (P/TBV)	0.00	6.89	3.20	3.87	0.00	7.46	5.44
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	-0.06	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	-0.06	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	0.48	-1.03	-1.02	-1.66	-10.47	-1.15
Leverage Ratio	-0.13	-8.92	1.04	1.13	2.25	15.50	1.34
Compound Leverage Factor	-0.14	-8.84	1.04	1.12	2.22	15.30	1.31
Debt to Total Capital	-6.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-6.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	106.19%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.53	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-0.53	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.53	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.44	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-0.44	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.44	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-12.41	50.33	55.96	5.05	-26.92	-9.58	-1.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.37	14.04	30.54	4.68	1.34	3.59	5.37
Quick Ratio	0.00	13.96	30.33	3.69	1.34	2.72	5.37
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-5.12	-9.52	-19	-18	-31	-19
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	-1.00	-0.53	-1.19	-0.05	-14	-1.24	-2.68
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	0.47	-0.66	1.14	-13	12	-1.44
Enterprise Value (EV)	12	44	97	81	186	59	72
Market Capitalization	12	52	142	110	192	69	92
Book Value per Share	($30.35)	$1.09	$5.49	$3.47	($0.76)	$0.67	$0.64
Tangible Book Value per Share	($30.35)	$1.09	$5.49	$3.47	($0.76)	$0.67	$0.64
Total Capital	-8.08	7.54	44	28	-7.75	9.31	17
Total Debt	0.50	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.50	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.50	-8.07	-46	-28	-5.75	-11	-20
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.27	-0.53	-1.19	-0.05	-4.28	-0.51	-3.64
Debt-free Net Working Capital (DFNWC)	-1.26	7.54	44	28	1.48	10	16
Net Working Capital (NWC)	-1.26	7.54	44	28	1.48	10	16
Net Nonoperating Expense (NNE)	-0.13	0.81	4.31	7.47	25	5.90	8.07
Net Nonoperating Obligations (NNO)	7.57	-8.07	-46	-28	-5.75	-11	-20
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.87)	($1.90)	$0.00	($6.23)	($2.02)	($1.40)
Adjusted Weighted Average Basic Shares Outstanding	0.00	6.95M	7.63M	0.00	9.02M	12.18M	20.55M
Adjusted Diluted Earnings per Share	$0.00	($0.87)	($1.90)	$0.00	($6.23)	($2.31)	($1.40)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	6.95M	7.63M	0.00	9.02M	12.24M	20.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.87)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	6.31M	8.16M	0.00	11.01M	19.49M	28.36M
Normalized Net Operating Profit after Tax (NOPAT)	-1.12	-4.65	-10	-18	-32	-19	-21
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Annovis Bio's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	9,012,273.00	10,262,273.00	11,011,299.00	11,171,480.00	13,054,018.00	13,797,242.00	19,486,231.00	19,486,231.00	19,486,231.00	26,502,889.00	28,355,262.00
DEI Adjusted Shares Outstanding	9,012,273.00	10,262,273.00	11,011,299.00	11,171,480.00	13,054,018.00	13,797,242.00	19,486,231.00	19,486,231.00	19,486,231.00	26,502,889.00	28,355,262.00
DEI Earnings Per Adjusted Shares Outstanding	-1.63	-2.16	-0.10	-0.45	-0.97	-0.43	-0.28	-0.32	-0.37	-0.37	-0.62
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-129.20%	-33.87%	88.86%	48.29%	14.06%	42.63%	-415.22%	-27.05%	41.95%	-66.95%	-209.96%
EBIT Growth	-129.20%	-33.87%	88.86%	48.29%	14.06%	42.63%	-415.22%	-27.05%	41.95%	-66.95%	-209.96%
NOPAT Growth	-129.20%	-33.87%	21.66%	20.46%	70.48%	35.50%	19.55%	19.21%	-69.45%	-44.12%	-186.70%
Net Income Growth	-128.80%	-187.51%	89.04%	47.36%	14.12%	73.60%	-418.96%	-23.90%	42.53%	-67.69%	-217.97%
EPS Growth	-106.33%	-148.94%	39.50%	58.88%	40.49%	92.31%	55.56%	27.27%	61.86%	-116.67%	-96.88%
Operating Cash Flow Growth	-135.00%	-159.46%	39.51%	64.87%	65.83%	11.53%	-15.16%	-51.28%	-8.94%	-7.74%	-11.27%
Free Cash Flow Firm Growth	-0.41%	193.10%	142.63%	158.24%	134.62%	-376.40%	-388.69%	-312.62%	-408.29%	68.44%	102.38%
Invested Capital Growth	-88.36%	-24,835.04%	-292.19%	-214.56%	-1,937.63%	90.79%	128.00%	120.88%	61.78%	-115.47%	-710.27%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-52.29%	29.74%	89.36%	-354.17%	-153.13%	53.10%	4.44%	-12.00%	-15.65%	-34.89%	-77.40%
EBIT Q/Q Growth	-52.29%	29.74%	89.36%	-354.17%	-153.13%	53.10%	4.44%	-12.00%	-15.65%	-34.89%	-77.40%
NOPAT Q/Q Growth	-52.29%	29.74%	25.21%	0.60%	43.48%	-53.50%	6.71%	0.18%	-18.55%	-30.55%	-85.58%
Net Income Q/Q Growth	-54.31%	-50.94%	95.20%	-370.54%	-151.74%	53.60%	5.59%	-12.33%	-16.76%	-35.41%	-79.03%
EPS Q/Q Growth	-52.34%	-43.56%	69.23%	38.89%	-120.45%	81.44%	-77.78%	0.00%	-15.63%	-5.41%	-61.54%
Operating Cash Flow Q/Q Growth	2.46%	0.05%	24.90%	52.01%	5.15%	-158.81%	2.25%	36.96%	31.69%	-155.96%	-0.95%
Free Cash Flow Firm Q/Q Growth	11.51%	175.80%	-28.34%	21.16%	-47.40%	-705.22%	25.15%	10.76%	23.74%	38.04%	105.64%
Invested Capital Q/Q Growth	-93.96%	-4,553.34%	51.94%	11.44%	3.06%	77.67%	246.09%	-33.97%	-277.50%	-25.86%	-313.75%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.01%	212.72%	96.02%	99.49%	98.94%	97.89%	96.72%	97.01%	97.95%	98.32%	99.22%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-202.26%	-546.40%	-566.49%	-453.01%	-596.70%	-3,159.09%	-280.78%	-365.03%	-246.14%	-220.61%	-301.13%
Cash Return on Invested Capital (CROIC)	-1,882.59%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,426.31%	-1,959.94%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-202.26%	-546.40%	-566.49%	-453.01%	-596.70%	-3,159.09%	-280.78%	-365.03%	-246.14%	-220.61%	-301.13%
Return on Equity Simple (ROE_SIMPLE)	-626.55%	0.00%	1,417.22%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-7.31	-5.47	-5.43	-3.07	-4.71	-4.40	-4.39	-5.20	-6.79	-13
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-22.49%	-87.33%	44.23%	4.19%	-100.75%	-14.11%	-8.98%	-17.32%	-14.74%	-20.21%	-27.42%
Return On Investment Capital (ROIC_SIMPLE)	-	94.31%	162.99%	310.35%	-43.48%	-50.65%	-18.28%	-23.95%	-39.56%	-40.32%	-403.34%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-15	-10	-1.11	-5.05	-13	-5.99	-5.72	-6.41	-7.41	-10	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-10	-1.11	-5.05	-13	-5.99	-5.72	-6.41	-7.41	-10	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	12.85	0.00	0.00	0.00	14.90	7.46	1.22	2.31	3.07	5.44	20.23
Price to Tangible Book Value (P/TBV)	12.85	0.00	0.00	0.00	14.90	7.46	1.22	2.31	3.07	5.44	20.23
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	261.06	0.00	0.00	0.00	0.00	0.00	3.85	20.96	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.93	-1.66	-1.19	-1.04	-1.38	-10.47	-1.23	-1.27	-1.38	-1.15	-1.34
Leverage Ratio	1.15	2.25	1.99	1.47	1.79	15.50	1.67	1.60	1.56	1.34	1.58
Compound Leverage Factor	1.14	4.78	1.91	1.46	1.77	15.18	1.61	1.55	1.53	1.32	1.57
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.68	-11.91	-12.92	-29.66	-6.11	-5.09	-0.43	-1.39	-7.02	1.47	-16.08
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.87	1.34	1.60	1.24	2.66	3.59	10.68	7.65	4.60	5.37	1.27
Quick Ratio	1.78	1.34	0.64	0.99	2.34	2.72	8.88	6.11	4.09	5.37	1.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.10	6.14	4.40	5.33	2.80	-17	-13	-11	-8.65	-5.36	0.30
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.30	-14	-6.49	-5.75	-5.57	-1.24	1.82	1.20	-2.13	-2.68	-11
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-2.30	-13	-9.87	-11	-5.88	12	8.31	6.95	3.44	-1.44	-13
Enterprise Value (EV)	79	186	128	60	93	59	6.99	25	25	72	49
Market Capitalization	86	192	131	64	105	69	29	42	40	92	63
Book Value per Share	$0.74	($0.76)	($0.30)	($0.16)	$0.54	$0.67	$1.23	$0.94	$0.68	$0.64	$0.11
Tangible Book Value per Share	$0.74	($0.76)	($0.30)	($0.16)	$0.54	$0.67	$1.23	$0.94	$0.68	$0.64	$0.11
Total Capital	6.66	-7.75	-3.35	-1.75	7.06	9.31	24	18	13	17	3.13
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-6.35	-5.75	-3.14	-4.00	-13	-11	-22	-17	-15	-20	-14
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.30	-4.28	-0.19	-3.01	-3.67	-0.51	2.00	1.52	-1.83	-3.64	-11
Debt-free Net Working Capital (DFNWC)	6.66	1.48	2.94	0.99	8.97	10	24	19	13	16	3.45
Net Working Capital (NWC)	6.66	1.48	2.94	0.99	8.97	10	24	19	13	16	3.45
Net Nonoperating Expense (NNE)	4.31	15	-4.40	-0.41	9.57	1.15	1.14	1.83	2.06	3.04	5.00
Net Nonoperating Obligations (NNO)	-6.35	-5.75	-3.14	-4.00	-13	-11	-22	-17	-15	-20	-14
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.63)	($2.34)	($0.10)	($0.44)	($0.97)	($0.51)	($0.32)	($0.32)	($0.37)	($0.39)	($0.63)
Adjusted Weighted Average Basic Shares Outstanding	9.01M	9.02M	10.63M	11.31M	12.98M	12.18M	17.43M	19.49M	19.69M	20.55M	27.85M
Adjusted Diluted Earnings per Share	($1.63)	($2.34)	($0.72)	($0.44)	($0.97)	($0.18)	($0.32)	($0.32)	($0.37)	($0.39)	($0.63)
Adjusted Weighted Average Diluted Shares Outstanding	9.01M	9.02M	10.82M	11.31M	12.98M	12.24M	17.43M	19.49M	19.69M	20.55M	27.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	10.26M	11.01M	11.17M	13.05M	13.80M	19.49M	19.49M	19.49M	26.50M	28.36M	34.65M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-7.31	-5.47	-5.43	-3.07	-4.71	-4.40	-4.39	-5.20	-6.79	-13
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Annovis Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Annovis Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Annovis Bio's net income appears to be on an upward trend, with a most recent value of -$28.85 million in 2025, rising from -$990.98 thousand in 2019. The previous period was -$24.59 million in 2024. See where experts think Annovis Bio is headed by visiting Annovis Bio's forecast page.

Annovis Bio's total operating income in 2025 was -$29.70 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $29.70 million

Over the last 6 years, Annovis Bio's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Annovis Bio's total liabilities were at $4.23 million at the end of 2025, a 8.4% decrease from 2024, and a 61.7% increase since 2019.

In the past 6 years, Annovis Bio's cash and equivalents has ranged from $1.86 thousand in 2019 to $45.69 million in 2021, and is currently $19.53 million as of their latest financial filing in 2025.

Over the last 6 years, Annovis Bio's book value per share changed from -30.35 in 2019 to 0.64 in 2025, a change of -102.1%.

Related Companies

Financial statements for NYSE:ANVS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Financials

Financials Breakdown Chart

Annovis Bio Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Financials

Annual Income Statements for Annovis Bio

Quarterly Income Statements for Annovis Bio

Annual Cash Flow Statements for Annovis Bio

Quarterly Cash Flow Statements for Annovis Bio

Annual Balance Sheets for Annovis Bio

Quarterly Balance Sheets for Annovis Bio

Annual Metrics And Ratios for Annovis Bio

Quarterly Metrics And Ratios for Annovis Bio

Financials Breakdown Chart

Annovis Bio Financials - Frequently Asked Questions

When does Annovis Bio's financial year end?

How has Annovis Bio's net income changed over the last 6 years?

What is Annovis Bio's operating income?

How has Annovis Bio's revenue changed over the last 6 years?

How much debt does Annovis Bio have?

How much cash does Annovis Bio have?

How has Annovis Bio's book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools